Phaxiam Therapeutics S.A. is a clinical-stage biopharmaceutical company specializing in the development of innovative bacteriophage-based therapies aimed at combating severe and resistant bacterial infections. The company is noted for its pioneering use of phages—natural viruses that selectively infect and destroy bacteria—which represents a targeted response to the growing challenge of antibiotic resistance. Phaxiam Therapeutics focuses its research on three of the most problematic bacteria linked to hospital-acquired infections: Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. These pathogens are responsible for a significant proportion of serious resistant infections globally. Through its specialized portfolio, Phaxiam addresses urgent needs in the healthcare sector, contributing to advances in infectious disease treatment where conventional antibiotics are increasingly ineffective. The company’s strategy and research have established it as a notable player within the biotechnology and medical research industries, particularly in the subsector of anti-infective therapeutics leveraging biological mechanisms for precision targeting of drug-resistant pathogens.